长春高新(000661) - 2015 Q2 - 季度业绩预告

Financial Performance - The net profit attributable to shareholders is expected to increase by 59.81% to 69.21% compared to the same period last year, with an estimated profit of between 170 million and 180 million CNY[2] - The basic earnings per share are projected to be approximately 1.29 to 1.37 CNY, compared to 0.81 CNY in the same period last year[2] - The increase in net profit is primarily due to the profit growth of subsidiary pharmaceutical companies and the increase in revenue from real estate development projects[4] Financial Reporting - The performance forecast has not been audited by a registered accountant[3] - The financial data is based on preliminary calculations by the company's finance department, with detailed financial data to be disclosed in the 2015 semi-annual report[5] - The performance forecast period is from January 1, 2015, to June 30, 2015[2] Investor Awareness - The company emphasizes the importance of investors being aware of investment risks[5] - The announcement was made by the board of directors on July 8, 2015[7]